

1) Dr. Ashwini Bhalerao-Gandhi

ICOG Guidelines for Management of Acute Pelvic Inflammatory Disease

Compiled by

Dr. Ashwini Bhalerao-Gandhi
Chairperson of the Adolescent Health Committee of FOGSI

Dr. Vanita Raut
Expert from Gp A Society - Mumbai

Dr. Gauri Karandikar
Expert from Gp B Society - Nasik

Dr. Neeta Dhabhai
Expert from Gp C Society - Faridabad

Dr. Ashok Shukla
PG Student from Mumbai

Dr. Papia Mukherjee
PG Student from Pondicherry

1. Introduction - Acute Pelvic Inflammatory Disease (PID) is a common cause of morbidity in women of reproductive age group (15-45 yrs). PID is usually the result of infection ascending from the endocervix causing endometritis, salpingitis, parametritis, oophoritis, tuboovarian abscess and / or pelvic peritonitis. It has a poly-microbial etiology. These guidelines apply to women requiring treatment for confirmed or suspected acute PID being treated in an outpatient or inpatient setting by primary and secondary care practitioners.
2. Transmission – In women aged less than 25 years, 60-80% of PID is usually caused by STI like gonorrhoea and / or chlamydia ^{3,4} plus anaerobic genital flora ^{3,5}. PID may occur occasionally by ascending spread of genital commensals including gram negative organisms, often following spontaneous or induced abortions, delivery, gynec procedures or surgeries etc. Causative organisms also include Gardnerella vaginalis, peptostreptococcus, bacteroides, ureaplasma, mycoplasma species etc. Sexually active women in their childbearing years are most at risk, and those under age 25 are more likely to develop PID, because the cervix of adolescent girls and young women is immature increasing its susceptibility to the STDS that are linked to PID. Multiple sexual partners, having a partner who has multiple partners put the women at a higher risk of acquiring PID. Women who douche have a higher risk as douching changes the vaginal flora and can force bacteria into the upper reproductive organs from the vagina. Women who have IUD inserted may have a slightly increased risk of PID immediately post insertion. Poor housing facilities and lack of sanitation may lead to poor menstrual hygiene in turn leading to PID.
3. Diagnosis
 - 3.1 Symptoms and Signs –



B Because of the lack of definitive clinical diagnostic criteria, a low threshold for empirical treatment of PID is recommended. Where there is diagnostic doubt or in clinically severe cases, admission to hospital for treatment and further investigations is advisable.

PID may cause a range of signs and symptoms from mild lower abdominal pain, leucorrhoea, dyspareunia, dysuria to even an acute abdomen. Symptoms may remain mild (particularly with chlamydia) or may become more severe over time. The diagnosis of PID is a clinical one. It should always be considered when diagnosing chlamydial and / or gonococcal cervical infection.

Minimum criteria for the diagnosis of Acute PID are :

Lower abdominal pain and tenderness, pain elicited on moving the cervix, adnexal tenderness / mass where other causes (especially ectopic pregnancy) have been excluded. Other additional criteria may be present but their absence does not exclude PID.

These additional criteria include –

Dyspareunia, abnormal vaginal or cervical discharge, positive chlamydia or gonorrhoea test result, change in menstrual bleeding pattern or abnormal bleeding in hormonal contraception use, fever (> 38.3°C) white cells on vaginal wet prep^{11,12}, elevated ESR, elevated c-reactive proteins¹⁷, lab documentation of cervical infection with N. gonorrhoea or chlamydia, USG findings of adnexal masses and free fluid in PID^{15,16}; Histopathology evidence of endometritis on endometrial biopsy; laparoscopic abnormalities consistent with PID.

3.2 Microbiological evaluation -

C Women with suspected PID should be screened for gonorrhoea and chlamydia.

Evidence of more than 10 WBCs / HPF on microscopic evaluation of a saline preparation of vaginal secretions is easy, cost-effective and favours a diagnosis of PID strongly. Endocervical swabs should be sent for microscopy, culture and sensitivity. Testing for gonorrhoea should be done with an endocervical specimen and tested via culture (direct inoculation on to a culture plate or transport of the swab to the laboratory within 24 hrs) or using a nucleic acid amplification test (NAAT). Screening for chlamydia should also be from the endocervix, preferably using a NAAT (e.g. PCR, strand displacement amplification). Taking an additional sample from the urethra increases the diagnostic yield for gonorrhoea and chlamydia. High vaginal swab also can be sent for culture. If a speculum examination cannot be done then self collected first catch urine or low vaginal swab for PCR testing and wet prep can be sent. Diagnosis of PID remains a clinical one on the basis of signs elicited on bimanual pelvic examination, regardless of swab results. Also, it should be noted that screening for gonorrhoea and chlamydia may not be feasible and economical in Indian setting. It is important to rule out presence of intra or extra uterine pregnancy or retained products of conception in women of child bearing age presenting with lower abdominal pain. In certain cases acute appendicitis should be ruled out. Laparoscopy enables specimens to be taken from the fallopian tubes and the pouch of Douglas and can provide information on the severity of the condition^{3,13}. Although it has been considered the gold standard in many studies of treatment regimens, 15-30% of suspected cases may have no laparoscopic evidence of acute infection despite organisms being isolated from the fallopian tubes^{3,10,14}. When there is diagnostic doubt, however, laparoscopy may be useful to exclude alternative pathologies^{3,14}.

4. Treatment for Acute PID –

4.1 The aims of treatment are relief of acute symptoms and prevention of long term sequelae like infertility, ectopic pregnancy, chronic pelvic pain and spontaneous abortions. Fertility is enhanced if the patients are treated within 48 hrs of onset of symptoms. Treatment should be initiated if the minimum criteria are met and no other causes are identified. The diagnosis is enhanced by the additional criteria, but their absence does not exclude PID. Hospital admission is recommended for all patients except those with mild disease.

4.2 Outpatient treatment -

A Outpatient antibiotic treatment should be commenced as soon as the diagnosis is suspected. In mild or moderate PID (in the absence of a tubo-ovarian abscess), there is no difference in outcome when patients are treated as outpatients or admitted to hospital¹⁹. It is likely that delaying treatment, especially in chlamydial infections, increases the severity of the condition and the risk of long-term sequelae such as ectopic pregnancy, subfertility and pelvic pain^{2,20}.

PID treatment regimens must provide empiric, broad spectrum coverage of likely pathogens. Several anti microbial regimens have been effective in achieving clinical and microbiologic cure. All treatment

regimens should be effective against *N. Gonorrhoea* and *C. trachomatis* because negative endocervical screening for these organisms does not rule out upper reproductive tract infection.

B Outpatient antibiotic treatment should be based on one of the following regimens : Recommended

Regimen A

- Oral Ofloxacin 400 mg twice a day plus oral Metronidazole 400mg twice a day for 14 days. ²¹⁻²⁴
- Oral Levofloxacin 500 mg once daily with oral Metronidazole 400mg twice daily for 14 days is also a good alternative as it has better compliance than twice daily dosage of Ofloxacin.

Regimen B

- IM Ceftriaxone 250mg single dose or IM Cefoxitin 2gm single dose with oral probenidicid 1 gm followed by oral doxycycline 100mg twice a day plus Metronidazole 400mg twice a day for 14 days. _{21,22,25-27}

Although the combination of oral doxycycline and metronidazole is in common use, there are no clinical trials assessing its effectiveness.⁶ There is insufficient evidence for including Azithromycin 1 gm orally as one stat dose in the treatment of PID but this is a common medication prescribed.



Concomitant vaginal discharge should be treated by suitable local medications.

The patient should be re-evaluated after 48-72 hrs to determine response to the outpatient treatment. Antibiotics should be revised according to clinical response and microbiological results.



Patients should be provided with a detailed explanation of their condition, with particular emphasis on the long-term implications for the health of themselves and their partner(s), reinforced with clear and accurate written information.

4.3 Inpatient treatment

Criteria for hospitalization in women with PID⁷

- Inability to exclude surgical emergency (e.g. appendicitis)
- Presence of tubo-ovarian abscess
- PID in pregnancy
- Clinically severe disease
- Failure to respond to outpatient oral therapy
- Intolerance to oral therapy (e.g. severe nausea / vomiting)

In more severe cases inpatient antibiotic treatment should be based on intravenous therapy which should be continued until 24 hours after clinical improvement and followed by oral therapy. Duration of treatment depends on the severity of disease and the response to the therapy. It should continue until symptoms and cervical tenderness have resolved, and for a minimum of 14 days. Laparoscopy is indicated if the diagnosis is doubtful or if rapid resolution of symptoms does not occur.



Recommended Regimens are:

Parenteral Regimen A

Cefotetan 2gm IV 12 hrly

Or

Cefoxitin 2gm IV 6 hrly

+

Doxycycline 100mg oral / IV every 12hrly for 48hrs followed by oral Doxycycline 100mg twice a day plus oral metronidazole 400 mg twice a day for 14 days. ^{7,21,22,26,27}

Parenteral Regimen B

Clindamycin 900 mg IV 8 hrly
+

Gentamicin IV / IM (2mg/kg load; then 1.5mg/kg 8 hrly) for 48 hrs followed by T.Doxycycline 100 mg BD plus oral metronidazole 400 mg BD for 14 days.

Or

T. Clindamycin 450mg QID for 14 days^{7,22,26,27}

If parenteral gentamicin is used, then serum drug levels and renal function should be monitored.

The combination of Inj. Ampicillin 500mg IV 6 hrly + Inj. Gentamicin 1.5mg/kg IV/IM 8 hrly + Inj. Metronidazole 500mg IV 8 hrly is sometimes used in India, but hardly any scientific evidence exists.

When selecting a treatment regimen, local antimicrobial sensitivity patterns, availability of drugs, their cost and patient acceptance should be considered.

4.4. Treatment in pregnancy

A pregnancy test should be performed in all women suspected of having PID to help exclude an ectopic pregnancy. In an ongoing intrauterine pregnancy, PID is extremely rare, except in the case of septic abortion. Cervicitis may occur, however, and is associated with increased maternal and fetal morbidity including pre-term delivery. Treatment regimens will be dependent upon the organisms isolated. Drugs known to be toxic in pregnancy should be avoided e.g.- Tetracyclines. Erythromycin and amoxicillin are not known to be harmful in pregnancy.

4.5. Treatment in children

Acute PID is rarely seen in very young girls. Ofloxacin can be used in such cases. In girls over the age of 12 yrs, even Doxycycline can be safely used.

4.6. Treatment in a woman with an intrauterine contraceptive device

B An intrauterine contraceptive device (IUCD) may be left in situ in women with clinically mild PID but should be removed in cases of severe disease.

4.7. Treatment in a woman with HIV

Women with PID who are also infected with HIV should be treated with the same antibiotic regimens as women who are HIV negative. Potential interactions between antibiotics and anti-retroviral medication needs to be considered on an individual basis. Low CD4 count is an indication for hospitalization.

5. Management of sexual partners of women with PID, which may be sexually acquired.

B Current sexual partners of women with PID should be contacted and offered health advice and screening for gonorrhoea and chlamydia.

If adequate screening is not possible, empirical therapy for both gonorrhoea and chlamydia should be given to the partner.^{31,32}

6. Other modes of treatment

B Surgical treatment should be considered in severe cases or where there is clear evidence of a pelvic abscess.

Laparotomy / Laparoscopy may help early resolution of the disease by division of adhesions and drainage of pelvic abscesses²⁸. Ultrasound-guided aspiration of pelvic fluid collections is less invasive and may

be equally effective^{29,30}. It is also possible to perform adhesiolysis in cases of peri-hepatitis due to chlamydia although there is no evidence as to whether this is superior to antibiotic therapy alone.

7. Follow up of patients with PID

C In the outpatient setting, review at 72 hours is recommended⁷, particularly for those with a moderate or severe clinical presentation.

Failure to improve suggests the need for further investigations, parenteral therapy and / or surgical intervention.

Further review four weeks after therapy may be useful to ensure:

- Adequate clinical response to treatment
- Compliance with oral antibiotics
- Screening and treatment of sexual contacts
- Awareness of the significance of PID and its sequelae.

If PCR is used as a test of cure, it should not be repeated before 3 weeks as persistent gonococcal and chlamydial DNA may lead to false positive results. If microscopy and culture are used as a test of cure, specimens should be taken at least 72 hrs after completion of treatment.

A full screen for all STDs including Hepatitis B & HIV should be offered for persistent infections.

8. Counselling issues

1. Importance of compliance with medication and completing the full course of treatment.
2. Regular follow-up in case of persistent symptoms.
3. Treatment of the partner is essential.
4. Avoid sexual intercourse until both patient and partner are fully treated.
5. Encouraged to use barrier contraceptives or dual protection.
6. Regular PAP smear as women with STI are also prone for HPV infection leading to CIN and cervical cancer.

9. Preventive Measures

- Reproductive Health Education to be given to young girls.
- Importance of menstrual hygiene to be reinforced.
- Safe sexual practices to be advocated.
- Pamphlets / Brochures regarding PID.
- Awareness programmes through mass media.

Grades of recommendations

A Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation.

B Requires the availability of well controlled clinical studies but no randomised clinical trials on the topic of recommendations.

C Requires evidence obtained from expert committee reports or opinions and / or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality.

Good Practice point

Recommended best practice based on the clinical experience of the guideline development group.

References :

1. RCOG Recommendations Royal College of Obstetricians and Gynaecologists Guideline No. 32 May 2003.

2. Hillis SD, Joesoef R, Marchbanks PA, Wasserheit JN, Cates W, Jr., Westrom L. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. *Am J Obstet Gynecol* 1993;168:1503-9.
3. Bevan CD, Johal BJ, Mumtaz G, Ridgway GL, Siddle NC. Clinical, laparoscopic and microbiological findings in acute salpingitis; report on a United Kingdom cohort. *BJOG* 1995;102:407-14.
4. Recommendations arising from the 31st Study Group: The Prevention of Pelvic Infection. In: Templeton A, editor. *The Prevention of Pelvic Infection*. London: RCOG Press; 1996: 267-70.
5. Baveja G, Saini S, Sangwan K, Arora DR. A study of bacterial pathogens in acute pelvic inflammatory disease. *J Commun Dis* 2001;33:121-5.
6. Ross JD. Outpatient antibiotics for pelvic inflammatory disease. *BMJ* 2001;322:251-2.
7. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. *MMWR Morb Mortal Wkly Rep* 2002;55:1-84.
8. PID-STD Treatment Guidelines 2006. Department of Health & Human Services Centers for Disease Control and Prevention.
9. Queensland Management Guidelines for the Detection and Treatment of Sexually Transmissible Diseases and Genital Infections.
10. Morcos R, Frost N, Hnat M, Petrunak A, Caldito G. Laparoscopic versus clinical diagnosis of acute pelvic inflammatory disease. *J Reprod Medullary* 1993;38:53-6.
11. Piepert JF, Ness RB, Blume J, Soper DE, Holley R, Randall H, et al. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. *Am J Obstet Gynecol* 2001;184:856-63.
12. Hakakha MM, Davis J, Korst LM, Silverman NS. Leukorrhea and bacterial vaginosis as in-office predictors of cervical infection in high-risk women. *Obstet Gynecol* 2002;100:808-12.
13. Kinghorn GR, Duerden BI, Hafiz S. Clinical and microbiological investigation of women with acute salpingitis and their consorts. *BJOG* 1986;93:869-80.
14. Cibula D, Kuzel D, Fucikova Z, Svabik K, Zivny J. Acute exacerbation of recurrent pelvic inflammatory disease. Laparoscopic findings in 141 women with a clinical diagnosis. *J Reprod Medullary* 2001;46:49-53.
15. Molander P, Sjoberg J, Paavonen J, Cacciatore B. Transvaginal power Doppler findings in laparoscopically proven acute pelvic inflammatory disease. *Ultrasound Obstet Gynecol* 2001;17:233-8.
16. Taipale P, Tarjanne H, Ylostalo P. Transvaginal sonography in suspected pelvic inflammatory disease. *Ultrasound Obstet Gynecol* 1995;6:430-4.
17. Miettinen AK, Heinonen PK, Laippala P, Paavonen J. Test performance of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of acute pelvic inflammatory disease. *Am J Obstet Gynecol* 1993;169:1143-9.
18. Wiesenfeld HC, Hillier SL, Krohn MA, Amortegui AJ, Heine RP, Landers DV, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. *Obstet Gynecol* 2002;100:456-63.
19. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. *Am J Obstet Gynecol* 2002;186:929-37.
20. Lepine LA, Hillis SD, Marchbanks PA, Joesoef MR, Peterson HB, Westrom L. Severity of pelvic inflammatory disease as a predictor of the probability of live birth. *Am J Obstet Gynecol* 1998;178:977-81.
21. Martens MG, Gordon S, Yarborough DR, Faro S, Binder D, Berkeley A. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. *South Med J* 1993;86:604-10.

22. Walker CK, Kahn JG, Washington AE, Peterson HB, Sweet RL. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. *J Infect Dis* 1993;168:969-78.
Soper DE, Brockwell NJ, Dalton HP. Microbial etiology of urban emergency department acute salpingitis: treatment with ofloxacin. *Am J Obstet Gynecol* 1992;167:653-60.
23. Peipert JF, Sweet RL, Walker CK, Kahn J, Rielly-Gauvin K. Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis). *Infect Dis Obstet Gynecol* 1999;7:138-44.
24. Arredondo JL, Diaz V, Gaitan H, Maradiegue E, Oyarzun E, Paz R, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild to moderate pelvic inflammatory disease in outpatients. *Clin Infect Dis* 1997;24:170-8.
25. Hemsell DL, Little BB, Faro S, Sweet RL, Ledger WJ, Berkeley AS, et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. *Clin Infect Dis* 1994;19:720-7
26. The European Study Group. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. *Acta Obstet Gynecol Scand* 1992;71:129-34.
27. Reich H, McGlynn F. Laparoscopic treatment of tuboovarian and pelvic abscess. *J Reprod Medullary* 1987;32:747-52.
28. Aboulghar MA, Mansour RT, Serour GI. Ultrasonographically guided transvaginal aspiration of tuboovarian abscesses and pyosalpinges: an optional treatment for acute pelvic inflammatory disease. *Am J Obstet Gynecol* 1995;172:1501-3.
29. Corsi PJ, Johnson SC, Gonik B, Hendrix SL, McNeeley SG Jr, Diamond MP. Transvaginal ultrasound-guided aspiration of pelvic abscesses. *Infect Dis Obstet Gynecol* 1999;7:216-21.
30. Haddon L, Heason J, Fay T, McPherson M, Carlin EM, Jushuf IH. Managing STIs identified after testing outside genitourinary medicine departments: one model of care. *Sex Transm Infect* 1998;74:256-7.
31. Groom TM, Stewart P, Kruger H, Bell G. The value of a screen and treat policy for *Chlamydia trachomatis* in women attending for termination of pregnancy. *J Fam Plann Reprod Health Care* 2001;27:69-72.

